Rockwell Medical Inc. (RMTI)
RMTI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1041024/000162828026021186/0001628280-26-021186-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RMTI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1998 |
| SEC CIK | 0001041024 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $69.3M |
| Net income | -$5.3M |
| Operating income | -$4.7M |
| Net margin | -7.7% |
| Operating margin | -6.8% |
| Revenue growth | -31.8% |
| Cash | $10.7M |
| Total assets | $57.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $10.6M cash; operating cash flow $670K a quarter. | Report 2026-09-30 |
| Shares outstanding | 4,030,465 (2026-08-10); 34,430,352 a year earlier; 28,489,663 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2026-07-01 | Source 2026-07-01 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-05-08 |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $20K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $19.1M | -$2.3M | -$1.5M | $10.6M | $9.1M | $72.6M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $17.8M | -$1.2M | $2.1M | $10.5M | $9.0M | $69.4M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $17.3M | -$1.6M | -$167K | $9.6M | $8.9M | $67.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $18.3M | -$554K | $2.3M | $10.7M | $8.8M | $69.3M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $15.9M | -$1.8M | -$1.3M | $13.6M | $8.7M | $75.6M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $16.1M | -$1.5M | $1.8M | $12.5M | $8.6M | $88.0M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $18.9M | -$1.5M | -$3.5M | $11.4M | $8.6M | $97.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $24.7M | -$756K | $865K | $15.7M | $8.5M | $101.5M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-11-13 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-05-11 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.1% |
| 1 month | -10.4% |
| 3 months | -10.2% |
| Year to date | -15.3% |
| 1 year | -22.7% |
| From 52-week high | -44.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| AARD | Aardvark Therapeutics Inc. | $1.26 | -5.26% | $27.6M |
| ACET | Adicet Bio Inc. | $2.75 | -1.08% | $25.7M |
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier